Logo Image
|Videos|July 14, 2017

What is The Fact-Track Cities Initiative?

Benjamin Young, MD, PhD, explains the Fast-Track Cities initiative.

Benjamin Young, MD, PhD, Senior Vice President, Chief Medical Officer, International Association of Providers in AIDS Care, explains the Fast-Track Cities initiative.

Interview Transcript (slightly modified for readability):

“The Fast-Track Cities initiative is a joint initiative between the International Association of Providers of AIDS Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), UN-Habitat, and the city of Paris. It is a four-way collaboration and those are the core partners.

[The initiative] was launched in 2015 with the goal of bringing cities and municipalities together to rapidly accelerate the implementation of the UNAIDS 2020 targets, namely, the 90-90-90 targets. We believe that cities are incubators for rapid acceleration of policy, and simultaneously, places where local governments are closer to the actual needs of the communities.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more